Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 37 articles: HTML format

Single Articles

June 2025
1. BUMA AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, et al
   Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al.
   Ann Oncol. 2025 Jun 2:S0923-7534(25)00198-X. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
2. RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al
   Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors.
   Ann Oncol. 2025;36:682-692.
   PubMed     Abstract available
   
   
   May 2025
3. DE MARINIS F, Kim TM, Bonanno L, Cheng S, et al
   Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH s
   Ann Oncol. 2025 May 22:S0923-7534(25)00157-7. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
4. LIU J, Shi Y, Yang Y
   Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.
   Ann Oncol. 2025 May 12:S0923-7534(25)00195-4. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
5. SZARPAK L, Pruc M, Bizon M, Olszewski M, et al
   Validation Study of Electronic Nose Detection for Lung Cancer.
   Ann Oncol. 2025 May 12:S0923-7534(25)00197-8. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
6. ROCCO G
   Letter to the Editor: Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath.
   Ann Oncol. 2025 May 12:S0923-7534(25)00196-6. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
7. FELIP E, Popat S, Dafni U, Ribi K, et al
   A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
   Ann Oncol. 2025;36:548-560.
   PubMed     Abstract available
   
   
   March 2025
8. BUMA AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, et al
   Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.
   Ann Oncol. 2025 Mar 31:S0923-7534(25)00125-5. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
9. FELIP E, Rojas CI, Schenker M, Kowalski DM, et al
   Subcutaneous Versus Intravenous Pembrolizumab, in Combination With Chemotherapy, for Treatment of Metastatic Non-Small Cell Lung Cancer: The Phase 3 3475A-D77 Trial.
   Ann Oncol. 2025 Mar 25:S0923-7534(25)00123-1. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
10. DI FEDERICO A, Hong L, Elkrief A, Thummalapalli R, et al
    Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors.
    Ann Oncol. 2025;36:297-308.
    PubMed     Abstract available
    
    
    January 2025
11. REMON J, Saw SPL
    Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
    Ann Oncol. 2025 Jan 22:S0923-7534(25)00012-2. doi: 10.1016/j.annonc.2025.
    PubMed    
    
    
    
12. HORINOUCHI H, Cho BC, Camidge DR, Goto K, et al
    Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib.
    Ann Oncol. 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    November 2024
13. FELIP E, Cho BC, Nguyen D, Curtin JC, et al
    Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto.
    Ann Oncol. 2024 Nov 8:S0923-7534(24)04060-2. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    October 2024
14. MEYER ML, Peters S, Mok TS, Lam S, et al
    Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action.
    Ann Oncol. 2024 Oct 14:S0923-7534(24)04055-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
15. NISHIMURA T, Fujimoto H
    PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
    Ann Oncol. 2024 Oct 11:S0923-7534(24)04059-6. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
16. HARRIS E, Taflin NF, Chitkara A, Tagliamento M, et al
    Time to rethink platinum choices in the era of immunotherapy in lung cancer.
    Ann Oncol. 2024 Oct 10:S0923-7534(24)04058-4. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
17. JOHN A, McDonald F, Popat S
    Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?
    Ann Oncol. 2024 Oct 10:S0923-7534(24)04054-7. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    September 2024
18. LU S, Ahn MJ, Reungwetwattana T, Ozguroglu M, et al
    Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
    Ann Oncol. 2024 Sep 11:S0923-7534(24)03823-7. doi: 10.1016/j.annonc.2024.08.2243
    PubMed     Abstract available
    
    
    June 2024
19. DI FEDERICO A, Alden SL, Smithy JW, Ricciuti B, et al
    Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.
    Ann Oncol. 2024 Jun 29:S0923-7534(24)00745-2. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
20. FELIP E, Cho BC, Gutierrez V, Alip A, et al
    Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
    Ann Oncol. 2024 Jun 26:S0923-7534(24)00702-6. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    May 2024
21. SCOTT S, Levy B
    New ADCs bring new questions in EGFR NSCLC and beyond.
    Ann Oncol. 2024;35:412-413.
    PubMed    
    
    
    
22. YU HA, Baik C, Kim DW, Johnson ML, et al
    Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Ann Oncol. 2024;35:437-447.
    PubMed     Abstract available
    
    
    April 2024
23. PETERS S, Loi S, Andre F, Chandarlapaty S, et al
    Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
    Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    March 2024
24. MOIK F, Riedl JM, Ay C
    Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Ann Oncol. 2024;35:327.
    PubMed    
    
    
    
25. PASSARO A, Wang J, Shah S, Bauml JM, et al
    Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl
    Ann Oncol. 2024;35:328-329.
    PubMed    
    
    
    February 2024
26. ROLFO C, Russo A
    Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer.
    Ann Oncol. 2024;35:147-149.
    PubMed    
    
    
    January 2024
27. SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al
    European cancer mortality predictions for the year 2024 with focus on colorectal cancer.
    Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
28. BUROTTO M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al
    Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally a
    Ann Oncol. 2024 Jan 8:S0923-7534(23)05112-8. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
29. PASSARO A, Wang J, Wang Y, Lee SH, et al
    Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Ann Oncol. 2024;35:77-90.
    PubMed     Abstract available
    
    
    
30. PRELAJ A, Miskovic V, Zanitti M, Trovo F, et al
    Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
    Ann Oncol. 2024;35:29-65.
    PubMed     Abstract available
    
    
    December 2023
31. FULTON-WARD T, Middleton G
    The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
    Ann Oncol. 2023;34:1113-1130.
    PubMed     Abstract available
    
    
    November 2023
32. TRAN HT, Heeke S, Sujit S, Vokes N, et al
    Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer.
    Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
33. SHIRAISHI Y, Sekino Y, Horinouchi H, Ohe Y, et al
    High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab.
    Ann Oncol. 2023;34:1064-1065.
    PubMed    
    
    
    October 2023
34. BORGHAEI H, de Marinis F, Dumoulin D, Reynolds C, et al
    SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Ann Oncol. 2023 Oct 11:S0923-7534(23)04019-X. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
35. JOHN A, Popat S
    Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
    Ann Oncol. 2023;34:829-830.
    PubMed    
    
    
    
36. GOUDA MA, Hu MI, Cabanillas ME, Wu J, et al
    Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
    Ann Oncol. 2023;34:946-948.
    PubMed    
    
    
    August 2023
37. BESSE B, Felip E, Campelo RG, Cobo M, et al
    Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
    Ann Oncol. 2023 Aug 1:S0923-7534(23)00790-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.